| Literature DB >> 33020516 |
Seung-Young Roh1, Dae In Lee2, Sung Ho Hwang3, Kwang-No Lee4, Yong-Soo Baek5, Mohammad Iqbal6, Dong-Hyeok Kim7, Jinhee Ahn8, Jaemin Shim9, Jong-Il Choi9, Young-Hoon Kim10.
Abstract
Atrial remodeling with fibrosis has been well-described in patients with atrial fibrillation (AF). We hypothesized that the left atrial (LA)-late gadolinium enhancement (LGE) extent on cardiac magnetic resonance (CMR) imaging is associated with LA pressure and can be a marker for suitable candidates for non-paroxysmal AF ablation. A total of 173 AF patients with an LA-LGE area on CMR imaging were enrolled. The clinical parameters, including invasively measured LA pressure, were compared between the patients with extensive LA-LGE (E-LGE, LGE extent ≥ 20%, n = 78) and those with small LA-LGE (S-LGE, LGE extent < 20%, n = 95). The E-LGE group had higher peak LA pressures than the S-LGE group (23 versus 19 mmHg, p < 0.001). The E-LGE group had more patients with non-paroxysmal AF (non-PAF) (51% vs. 34%), heart failure (9% vs. 0%), and higher NT pro-B-type natriuretic peptide (472 vs. 265 pg/ml) (all p < 0.05). LA pressure ≥ 21 mmHg was an independent predictor of E-LGE (OR = 2.218; p = 0.019). In the paroxysmal AF (PAF) subgroup, freedom from atrial arrhythmia after catheter ablation was not different (81% vs 86%, log-rank p = 0.529). However, in the non-PAF subgroup, it was significantly higher in the S-LGE group than in the E-LGE group (81% vs 55%, log-rank p = 0.014). Increased LA pressure was related to the LA-LGE extent. LA-LGE was a good predictor of outcome after catheter ablation, but only in patients with non-PAF.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33020516 PMCID: PMC7536288 DOI: 10.1038/s41598-020-72929-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow chart showing the study design and representative LGE-CMR images of the E-LGE and S-LGE groups. Pts patients, CMR cardiac magnetic resonance, LAP left atrial pressure, LGE late gadolinium enhancement, LA left atrial, LAP left atrial pressure, Ant anterior, Post posterior.
Baseline characteristics of study population.
| E-LGE group (n = 78) | S-LGE group (n = 95) | ||
|---|---|---|---|
| Age (years) | 57 ± 10 | 56 ± 11 | 0.540 |
| Male gender | 62 (80) | 78 (82) | 0.403 |
| Body mass index (kg/m2) | 26 ± 5 | 25 ± 3 | 0.099 |
| Non-paroxysmal AF | 40 (51) | 32 (33) | 0.021 |
| Diagnosis to ablation time (month) | 43 ± 34 | 46 ± 46 | 0.655 |
| Hypertension | 27 (35) | 38 (40) | 0.285 |
| Diabetes mellitus | 5 (6) | 9 (10) | 0.328 |
| Thromboembolism | 6 (8) | 8 (8) | 0.545 |
| History of heart failure | 7 (9.0) | 0 | 0.003 |
| Coronary artery disease | 4 (5) | 5 (5.3) | 0.622 |
| Chronic kidney disease | 3 (4) | 3 (3.2) | 0.562 |
| Thyroid disease | 5 (6) | 7 (7) | 0.525 |
| CHADS2 VASc ≥ 2 | 29 (37) | 32(34) | 0.374 |
| LGE area (%) | 29 ± 8 | 11 ± 5 | < 0.001 |
| LA volume (ml) | 96 ± 34 | 87 ± 29 | 0.091 |
| LA volume index (ml/m2) | 54 ± 20 | 49 ± 17 | 0.085 |
| LV mass index (g/m2) | 87 ± 16 | 91 ± 16 | 0.113 |
| LV ejection fraction (%) | 57 ± 6 | 58 ± 4 | 0.465 |
| E/Em ratio | 8.5 ± 2.5 | 9.2 ± 4.0 | 0.192 |
| Estimated PASP (mmHg) | 28 ± 7 | 26 ± 8 | 0.265 |
| Spontaneous echo contrast | 20 (25.6) | 16 (16.8) | 0.109 |
| LAPpeak (mmHg) | 23 ± 6 | 19 ± 5 | < 0.001 |
| LAPnadir (mmHg) | 9 ± 4 | 8 ± 4 | 0.006 |
| LAPmean (mmHg) | 14 ± 4 | 12 ± 4 | < 0.001 |
Data are presented as n (%) or mean ± standard deviation and analyzed using χ2 test and unpaired two-tailed t-test or Fisher’s exact test.
AF atrial fibrillation, CMR cardiac magnetic resonance, LGE late gadolinium enhancement, LA left atrial, LV left ventricular, PASP pulmonary artery systolic pressure, LAP left atrial pressure.
Figure 2The relationship between measured left atrial pressure and late gadolinium enhancement (LGE) extent in cardiac magnetic resonance. Each point on the plots represents a value of the LGE extent in one patient. R and P represent Pearson's correlation coefficients and the corresponding P-values. LA left atrial, LGE late gadolinium enhancement, LA pressure left atrial pressure.
Univariate and multivariate analysis (Logistic regression) showing odds ratio to predict E-LGE (LGE ≥ 20%).
| Variables | Univariate odds ratio (95% CI) | Multivariate odds ratio (95% CI) | ||
|---|---|---|---|---|
| Age, 1 year | 1.009 (0.980–1.039) | 0.538 | ||
| Female sex | 1.184 (0.554–2.531) | 0.663 | ||
| Non-paroxysmal AF | 2.072 (1.120–3.833) | 0.020 | 1.835 (0.899–3.747) | 0.096 |
| Diagnosis to ablation time (month) | 0.998 (0.991–1.006) | 0.998 | ||
| Body mass index (kg/m2) | 1.077 (0.986–1.177) | 0.100 | 1.063 (0.964–1.171) | 0.222 |
| CHADS2 VASc score ≥ 2 | 1.165 (0.623–2.179) | 0.632 | ||
| LV ejection fraction (%) | 0.978 (0.922–1.038) | 0.978 | ||
| E/Em ratio | 0.937 (0.843–1.041) | 0.223 | ||
| LA volume index (ml/m2) | 1.015 (0.998–1.032) | 0.082 | 1.009 (0.989–1.029) | 0.399 |
| NT Pro BNP (pg/ml) | 1.001 (1.000–1.002) | 0.025 | 1.001 (1.000–1.002) | 0.157 |
| LA pressure ≥ 21 mmHg | 2.235 (1.213–4.118) | 0.010 | 2.218 (1.138–4.324) | 0.019 |
AF atrial fibrillation, LV left ventricular, LA left atrial, NT Pro BNP N terminal brain natriuretic peptides.
Figure 3Kaplan–Meier survival curve showing atrial fibrillation (AF)/atrial tachycardia (AT)-free survival with the proportion of patients in sinus rhythm against the follow-up time in days. (A) AF/AT-free survival in the total population, (B) AF/AT-free survival in the subgroup with paroxysmal AF, (C) AF/AT-free survival in the subgroup with non-paroxysmal AF.